Showing 3891-3900 of 5660 results for "".
- Air Pollution Linked to Increased Psoriasis Burden: Meta-Analysishttps://practicaldermatology.com/news/air-pollution-linked-to-increased-psoriasis-burden-meta-analysis/2486409/New research presented at AAD 2026 suggests airborne pollutant particulate matter less than 2.5 microns in diameter (PM2.5), PM10, and NO2 showed the most consistent positive associations with psoriasis incidence in severity, and health care utilization.
- Study: Potential Link Between Lesional IgG Autoantibodies and HS Disease Severityhttps://practicaldermatology.com/news/study-suggests-potential-link-between-lesional-igg-autoantibodies-and-hs-disease-severity/2486348/A small biopsy-based study in the Journal of Investigative Dermatology Innovations adds to emerging evidence that humoral immunity may contribute to hidradenitis suppurativa (HS) pathobiology. Investigators analyzed
- ADorable-1 Trial Meets Endpoints for EBGLYSS in Children With Atopic Dermatitishttps://practicaldermatology.com/news/adorable-1-trial-meets-endpoints-for-ebglyss-in-children-with-atopic-dermatitis/2486087/Eli Lilly and Company announced positive topline results from the phase 3 ADorable-1 trial of lebrikizumab-lbkz (Ebglyss) in pediatric patients aged 6 months to 18 years with moderate-to-severe atopic dermatitis (AD), showing the therapy meeting its primary and sec
- Review: Gut Microbiota Dysbiosis Linked With AD, Psoriasis, and HShttps://practicaldermatology.com/news/review-gut-microbiota-linked-with-dysbiosis-with-ad-psoriasis-and-hs/2485997/A new systematic review suggests that alterations in gut microbial composition may contribute to atopic dermatitis (AD), psoriasis, and hidradeni
- Study: Bimekizumab Not Linked to Higher Depression Risk vs. IL-23 Inhibitorshttps://practicaldermatology.com/news/study-bimekizumab-not-linked-to-higher-depression-risk-vs-il-23-inhibitors/2485849/Bimekizumab was not associated with increased risk of depression or suicidal ideation compared with IL-23 inhibitors, a new study from George Washington University indicated. "Bimekizumab, a dual IL-17A/F inhibitor, has demons
- Analysis: Biologics Linked to Lower Cardiometabolic Risk in HShttps://practicaldermatology.com/news/analysis-biologics-linked-to-lower-cardiometabolic-risk-in-hs/2485805/Biologics were associated with a lower incidence of type 2 diabetes mellitus (T2DM) and cardiovascular events vs. no biologic use in a TriNetX cohort of 291,283 patients with hidradenitis suppurativa (HS), according to a new study in the Journal of Drugs in Dermatology. Investigat
- Study: HS Linked to Hyperglycemia and Altered Amino Acid Metabolism in Plasmahttps://practicaldermatology.com/news/study-hs-linked-to-hyperglycemia-and-altered-amino-acid-metabolism-in-plasma/2485657/New research in the Archives of Dermatological Research shows consistent metabolic alterations in patients with moderate-to-severe hidradenitis suppurativa (HS, particiularly regarding energy and amino acid metabolism, that
- Analysis: Agent Orange Exposure Linked to Acral Melanoma Risk in US Veteranshttps://practicaldermatology.com/news/analysis-agent-orange-exposure-linked-to-acral-melanoma-risk-in-us-veterans/2485639/Acral melanoma (AM), a rare melanoma subtype, showed risk factor patterns in a large Veterans Affairs (VA)–based analysis spanning more than two decades, according to new data. In this case-control study of US veterans from 20
- Fever and Abdominal Purpura Linked to IgAV Recurrence in Adultshttps://practicaldermatology.com/news/fever-and-abdominal-purpura-linked-to-igav-recurrence-in-adults/2485592/Systemic corticosteroids and post-bacterial etiology may protect against recurrence or relapse in adult immunoglobulin A vasculitis (IgAV), a new study suggests. Investigators for the retrospective cohort study
- Rapid Regrowth Tops Treatment Goals for Alopecia Areata: Surveyhttps://practicaldermatology.com/news/rapid-regrowth-tops-treatment-goals-for-alopecia-areata-survey-finds/2485419/Results from a new national survey presented at the 2026 Winter Clinical Dermatology Hawaii reveals that most US clinicians prioritize rapid and nearly complete hair regrowth, with strong satisfaction reported for Janus kinase (JAK) inhibitor therapies.